Backs FY25 adjusted EBITDA view loss of $35M. The company said, ‘The Company expects full year 2025 gross margins in the range of 64.0% to 64.5%. The Company expects a gross margin headwind of approximately $2.0 million in the fourth quarter, attributable to tariff-related costs.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PRCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Procept Biorobotics’ WATER IV Study: A Game Changer in Prostate Cancer Treatment?
- Procept Biorobotics’ Aquablation Therapy Study: A Potential Game-Changer for Prostate Treatment
- Buy Rating Affirmed Amid Potential Upside and Strategic Leadership Changes
- Procept BioRobotics price target lowered to $50 from $64 at Truist